501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604)
551-7831
Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies To Present at Texas Impaired Driving Forum, Provides
Corporate Update
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia --
December 9, 2021 -- InvestorsHub NewsWire -- Cannabix Technologies
Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of
marijuana breathalyzer devices for law enforcement and the
workplace reports
that it will be
presenting at the Texas Impaired Driving Forum, held by Texas
A&M Transportation Institute (TTI) in
February. Cannabix's Dr. Jared Boock Ph.D.,
will be presenting the Company's marijuana breathalyzer
technologies and approaches at the Forum. The 2021 Texas Impaired
Driving Forum attracted approximately 300 attendees from across the
state of Texas. These traffic safety stakeholders specialize in
fields such as prosecution, judicial review, probation, law
enforcement, education/advocacy, prevention, treatment, and highway
safety.
THCBA update
The Company reports that the
version 4.0 THC Breath Analyzer ("THCBA") sensor apparatus for
production is being bench tested with preliminary standardized
testing showing that this updated design results in less than half
of the standard deviation variability of the successful previous
version 3.0 sensor. This updated sensor apparatus design and
related hardware improvements have been developed incorporating
feedback from beta-test users as well as planned design changes
which have been prepared over the past months. Several components such as the
device's internal sampling chambers, microfluidic sensors and
related actuation mechanism have been simplified to minimize
manufacturing variability and to reduce cost. The first fully assembled version
4.0 THCBA devices for human testing are on track for December -
this will be followed by broad field testing and clinical testing
to establish V4.0 benchmark standards.
The THCBA is a drug screening
device for various markets who are seeking a way to quickly (in
less than 5 minutes), easily and non-invasively test for recent use
of ?9-tetrahydrocannabinol ("THC") - the psychoactive component of
marijuana that causes impairment. The THCBA consists of a handheld
device and protective case which houses a sterilization module,
sample preparation stage, device recovery station and integrated
battery charging system.
Germany
Recently, the leaders of all three
parties that make up the German coalition government entered into a
four-year coalition agreement that sets out a commitment to
"introduce the controlled distribution of cannabis to adults for
recreation." With a population of over 83 million, Germany could be
become one of the largest legal cannabis markets in the world. The
Company reports that it has been in discussions with companies in
Germany for the advancement of Cannabix marijuana breath testing
tools and may allocated resources as necessary to take advantage of
these opportunities.
Dr. Richard Yost
Dr. Richard Yost (Ph.D.) of the
University of Florida (UF) has entered into a consulting agreement
with the Company as well as maintaining his role as Senior
Scientific Advisor in the area of FAIMS technology
development. Dr. Yost is the winner of the
Pittsburgh (Pittcon) Analytical Chemistry Award for 2021. Dr. Yost
is widely recognized as a world leader in the field of mass
spectrometry and analytical chemistry, most notably for his
co-invention of the triple quadrupole mass spectrometer, which has
revolutionized important measurements impacting human health and
well-being in the fields of drug metabolism, pharmacokinetics,
environmental studies, and biological analyses. The consulting
agreement with Dr. Yost has been adopted, as the Company's research
term with UF has ended.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law enforcement
to identify recent marijuana use that
better aligns with impairment. Cannabix devices are in the advanced
prototype and pre-clinical testing stage.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information, contact
the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities. The Company is not currently
selling commercial breathalyzers. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.
